Literature DB >> 27388688

Sex differences in morning cortisol in youth at ultra-high-risk for psychosis.

Emily E Carol1, Robert L Spencer2, Vijay A Mittal3.   

Abstract

Research suggests abnormalities in hypothalamic-pituitary-adrenal (HPA) axis function play an important role in the pathophysiology of psychosis. However, there is limited research on the biological stress system in young people at ultra high risk (UHR) for psychosis. Morning cortisol levels are particularly relevant to study in this context, as these markers reflect HPA regulation. This is the first examination of sex differences in morning cortisol levels in UHR individuals. Twenty-eight UHR and 22 matched healthy control participants were assessed in respect to symptoms and had home-based collection of salivary cortisol over three time points in the morning. It was predicted that the UHR participants would exhibit lower morning cortisol levels and lower cortisol would be associated with greater symptomatology (i.e. higher positive, negative, and depressive symptoms). Additionally, sex differences in morning cortisol levels were explored based on recent evidence suggesting that sex differences may play an important role in the exacerbation of psychosis. While there were no group differences in morning salivary cortisol secretion, there was a sex by time interaction among UHR individuals, such that only UHR males exhibited flat cortisol levels across two hours after awakening, whereas UHR females had a pattern of cortisol secretion similar to healthy controls, even among medication-free individuals (F=6.34, p=0.004). Cortisol AUC (area under the curve) across the three time points had a trend association (medium effect size; r=0.34, p=0.08) with depressive, but not positive or negative, symptom severity. These results stress the importance of considering sex differences in the psychosis-risk period, as they improve understanding of pathogenic processes. Published by Elsevier Ltd.

Entities:  

Keywords:  Cortisol; HPA axis; High-risk; Prodrome; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27388688      PMCID: PMC4996727          DOI: 10.1016/j.psyneuen.2016.06.013

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  63 in total

1.  Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents.

Authors:  C S Martin; N K Pollock; O G Bukstein; K G Lynch
Journal:  Drug Alcohol Depend       Date:  2000-05-01       Impact factor: 4.492

Review 2.  Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies.

Authors:  R Grant Steen; Courtney Mull; Robert McClure; Robert M Hamer; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2006-06       Impact factor: 9.319

3.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

4.  Clinical high risk for psychosis: gender differences in symptoms and social functioning.

Authors:  Liz Rietschel; Martin Lambert; Anne Karow; Mathias Zink; Hendrik Müller; Andreas Heinz; Walter de Millas; Birgit Janssen; Wolfgang Gaebel; Frank Schneider; Dieter Naber; Georg Juckel; Seza Krüger-Özgürdal; Thomas Wobrock; Michael Wagner; Wolfgang Maier; Joachim Klosterkötter; Andreas Bechdolf
Journal:  Early Interv Psychiatry       Date:  2015-03-24       Impact factor: 2.732

5.  Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study.

Authors:  Alexandra Soliman; Gillian A O'Driscoll; Jens Pruessner; Anne-Lise V Holahan; Isabelle Boileau; Danny Gagnon; Alain Dagher
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

6.  Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.

Authors:  Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante
Journal:  Schizophr Res       Date:  2009-09-13       Impact factor: 4.939

7.  Exposure to postnatal depression predicts elevated cortisol in adolescent offspring.

Authors:  Sarah L Halligan; Joe Herbert; Ian M Goodyer; Lynne Murray
Journal:  Biol Psychiatry       Date:  2004-02-15       Impact factor: 13.382

8.  Gender and the course of schizophrenia: differences in treated outcomes.

Authors:  M C Angermeyer; L Kühn; J M Goldstein
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

9.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06

Review 10.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

View more
  3 in total

1.  The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Authors:  Emily E Carol; Robert L Spencer; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2017-05-30       Impact factor: 4.905

2.  Stress, Cortisol and NR3C1 in At-Risk Individuals for Psychosis: A Mendelian Randomization Study.

Authors:  Anton Iftimovici; Oussama Kebir; Qin He; Thérèse M Jay; Guy A Rouleau; Marie-Odile Krebs; Boris Chaumette
Journal:  Front Psychiatry       Date:  2020-07-10       Impact factor: 4.157

Review 3.  Markers of Schizophrenia-A Critical Narrative Update.

Authors:  Beata Galińska-Skok; Napoleon Waszkiewicz
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.